US 11,912,987 B2
Methods for screening for cancer targets
Micah Benson, Arlington, MA (US)
Assigned to KSQ Therapeutics, Inc., Lexington, MA (US)
Filed by KSQ Therapeutics, Inc., Cambridge, MA (US)
Filed on Jun. 24, 2021, as Appl. No. 17/356,988.
Application 17/356,988 is a continuation of application No. 15/668,652, filed on Aug. 3, 2017, granted, now 11,078,481.
Claims priority of provisional application 62/370,560, filed on Aug. 3, 2016.
Prior Publication US 2021/0317443 A1, Oct. 14, 2021
Prior Publication US 2022/0154178 A9, May 19, 2022
Int. Cl. C40B 30/04 (2006.01); C12N 15/10 (2006.01); C07K 14/715 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C12N 5/09 (2010.01); C12N 9/22 (2006.01); C12N 5/0783 (2010.01)
CPC C12N 15/1086 (2013.01) [C07K 14/70596 (2013.01); C07K 14/7153 (2013.01); C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); C12N 5/0636 (2013.01); C12N 5/0693 (2013.01); C12N 9/22 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/53 (2013.01); C12N 2501/599 (2013.01); C12N 2502/1114 (2013.01); C12N 2502/30 (2013.01); C40B 30/04 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method comprising:
(a) co-culturing (i) engineered tumor cells that comprise an extracellular protein and (ii) edited T cells that comprise a chimeric antigen receptor (CAR) that comprises an extracellular target-binding domain that binds to the extracellular protein, wherein the edited T cells comprise a Cas9 protein and a guide RNA (gRNA) library that comprises gRNAs targeting one or more genomic loci in the edited T cells; and
(b) isolating the edited T cells that accumulate during the co-culturing.